Desvenlafaxine

Indications & formulation #

Major depressive disorder in adults. This reference covers the selected formulation; other indications and products need their own evidence.

Dose reference #

Adult educational reference · Oral extended-release tablet · United States. The clinician selects treatment after assessment; this page does not calculate or change a prescription.

50 mg once daily is the starting and therapeutic dose. Higher doses showed no additional average benefit and more adverse effects. Swallow whole.

Contraindications & important cautions #

Avoid MAOIs and hypersensitivity to venlafaxine/desvenlafaxine. Assess blood pressure, activation and serotonin toxicity.

Selected important cautions; consult the full product information for all contraindications and warnings.

Adverse effects #

Nausea, sweating, sexual effects, blood-pressure changes and withdrawal symptoms may occur.

Interactions #

Assess serotonergic combinations, MAO inhibitors and renal function; do not infer equivalence to a venlafaxine regimen.

Monitoring #

Review blood pressure, renal context, symptoms and adverse effects using the selected extended-release product information.

Special populations #

CrCl 30–50: maximum 50 mg/day; CrCl 15–29 or end-stage disease: maximum 25 mg/day or 50 mg alternate days. No post-dialysis supplement.

Adult scope. Pregnancy, breastfeeding and pediatric use require the exact product’s population-specific guidance and individual assessment.

Discontinuation, restarting & counseling #

Reduce gradually; 25 mg tablets may support discontinuation.

Brands & products #

Reference coverage #

Structured summary of selected adult uses, not an exhaustive monograph. Indian product authorization and local prescribing requirements have not been reconciled.